Disruption of epigenetic regulation of enhancers in the germinal center reaction drives clonal evolution in Follicular Lymphoma
生发中心反应中增强子表观遗传调控的破坏驱动滤泡性淋巴瘤的克隆进化
基本信息
- 批准号:10218056
- 负责人:
- 金额:$ 4.6万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-07-06 至 2023-07-05
- 项目状态:已结题
- 来源:
- 关键词:AccountingAdaptive Immune SystemAddressAffectAffinityAmerican Cancer SocietyApoptosisApoptoticAutomobile DrivingB-Cell Antigen ReceptorB-LymphocytesBCL2 geneBiological AssayBone MarrowCREBBP geneCellsCellular AssayChimera organismChromatinClonal EvolutionClonal ExpansionComplexDataDevelopmentDiagnosisDiseaseEnhancersEpigenetic ProcessEventFollicular LymphomaFounder GenerationFrequenciesGene ExpressionGene Expression ProfileGenesGeneticGenetic TranscriptionGenotypeHeterozygoteHistonesHumanIGH@ gene clusterImmunoglobulin Somatic HypermutationIndividualIndolentLymphomaLymphoma cellLysineMalignant - descriptorMediatingMethyltransferaseModelingMusMutationNatureNon-Hodgkin&aposs LymphomaNonsense MutationPatient MonitoringPoint MutationProcessReactionRecyclingReportingRoleSamplingSomatic MutationStructure of germinal center of lymph nodeSymptomsTimeXCL1 genebaseclinical practicedifferential expressionepigenetic regulationhistone acetyltransferasehistone methyltransferasehuman diseaselarge cell Diffuse non-Hodgkin&aposs lymphomaloss of functionmouse modelpreventprogramsstemtumor
项目摘要
PROJECT SUMMARY/ABSTRACT
Follicular Lymphoma (FL) is the second most common form of non-Hodgkin's lymphoma, accounting for 20-
30% of non-Hodgkin's lymphoma diagnoses. Though FL is an indolent disease, it eventually transforms into
more aggressive, incurable forms of lymphoma. FL is hallmarked by the anti-apoptotic IGH/BCL2 translocation,
which is often accompanied by a mutation in an epigenetic gene. Here, we propose to investigate the roles of
these mutations in epigenetic genes, specifically KMT2D and CREBBP due to their high rate of occurrence, in
the development and transformation process of FL. In our first aim, we plan to use mixed bone marrow chimera
mouse models to determine the role of these mutations in driving early clonal evolution of the disease. In our
second aim, we plan to then characterize the gene expression and chromatin accessibility of the resulting
lymphoma to determine how these mutations cooperate to drive progression through epigenetic reprogramming
of the tumor.
项目摘要/摘要
卵泡淋巴瘤(FL)是非霍奇金淋巴瘤的第二大最常见形式,占20-
非霍奇金淋巴瘤诊断的30%。尽管FL是一种懒惰的疾病,但它最终转化为
更具侵略性,无法治愈的淋巴瘤形式。 FL是由抗凋亡IGH/BCL2易位标志的
通常伴随着表观遗传基因中的突变。在这里,我们建议调查
这些突变在表观遗传基因中,特别是KMT2D和CREBBP,因为它们的发生率很高
FL的发展和转变过程。在我们的第一个目标中,我们计划使用混合的骨髓嵌合体
小鼠模型确定这些突变在驱动疾病早期克隆进化中的作用。在我们的
第二个目的,我们计划表征所得的基因表达和染色质可及性
淋巴瘤确定这些突变如何通过表观遗传重编程驱动进展
肿瘤。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Christopher Russell Chin其他文献
Christopher Russell Chin的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Christopher Russell Chin', 18)}}的其他基金
Disruption of epigenetic regulation of enhancers in the germinal center reaction drives clonal evolution in Follicular Lymphoma
生发中心反应中增强子表观遗传调控的破坏驱动滤泡性淋巴瘤的克隆进化
- 批准号:
10444918 - 财政年份:2020
- 资助金额:
$ 4.6万 - 项目类别:
相似海外基金
Early Onset Parkinson’s disease subtypes and pathogenic mechanisms
早发性帕金森病亚型及致病机制
- 批准号:
10719645 - 财政年份:2023
- 资助金额:
$ 4.6万 - 项目类别:
Goblet cells and intestinal immune response in alcohol-associated liver disease
酒精相关性肝病中的杯状细胞和肠道免疫反应
- 批准号:
10446819 - 财政年份:2022
- 资助金额:
$ 4.6万 - 项目类别:
Retroviral RLI immunomodulatory gene therapy for glioblastoma
逆转录病毒 RLI 免疫调节基因治疗胶质母细胞瘤
- 批准号:
10522026 - 财政年份:2022
- 资助金额:
$ 4.6万 - 项目类别:
Goblet cells and intestinal immune response in alcohol-associated liver disease
酒精相关性肝病中的杯状细胞和肠道免疫反应
- 批准号:
10681329 - 财政年份:2022
- 资助金额:
$ 4.6万 - 项目类别:
Tissue-based biomarkers of anti-PD-1-based therapy in metastatic renal cell carcinoma
转移性肾细胞癌抗 PD-1 疗法的组织生物标志物
- 批准号:
10645216 - 财政年份:2022
- 资助金额:
$ 4.6万 - 项目类别: